Previous 10 | Next 10 |
2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...
2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...
2024-04-26 15:56:40 ET Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the TGCT indication, as the only approved therapy is ...
2024-04-26 15:00:06 ET More on the markets SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason BofA watched clients retract $2B last week as th...
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY PR Newswire THOUSAND OAKS, Calif. , April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Appl...
2024-04-26 05:00:00 ET Summary We are long-term, patient, and active value investors. Our mission is to be responsible stewards in our clients’ financial lives and seek long-term growth of capital. After discussing GrafTech's challenges throughout 2022 and 2023, Groundhog D...
2024-04-25 18:33:59 ET Summary CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD...
2024-04-25 08:37:36 ET More on AstraZeneca AstraZeneca: What The Market's Missing What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca beats top-line and bottom-line estimates; ...
2024-04-22 12:53:43 ET More on S&P 500 Index: Fed's Commercial Banking Report Shows Economic Headwinds, But Deposit Growth Bucks Trend S&P 500: Capitulation? Week Starting 22nd April (Technical Analysis) Powell Playing Games: 'Sell In May' Is Now 'Sell Before...
2024-04-22 12:03:00 ET Summary The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom. The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...